Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Two Healthcare Stocks Are Advancing but See Which One Hedge Funds Sentiment Suggest is Better

Page 1 of 2

The markets opened lower on Friday on the back of Fed’s decision not to raise interest rates, which reduced investors back to uncertainty and signaled further worries regarding the financial markets and the global economy. However, two healthcare stocks gained ground in the first hours of trading, including TRACON Pharmaceuticals Inc (NASDAQ:TCON), which surged by around 40% on the back of positive study results. In this article we will take a closer look at the developments that moved both stocks higher today and will also see how hedge funds have been trending them in order to better understand the long-term potential of these investment opportunities.


The hedge fund sentiment is a metric that is often overlooked, because many think that hedge funds are not good investors to emulate because of their lagging returns in the last years. However, what is important to point out is that the weak returns of equity hedge funds come mainly from their hedging positions, which represent a necessary precaution if we take into account hedge funds’ large sizes. Our research that involved analyzing the equity portfolios of several hundred hedge funds between 1999 and 2012, has shown that hedge funds are still very skilled at picking investments on the long side of their portfolios. This is particularly observable among their small-cap ideas, which showed returns of almost one percentage point above the market in backtests. Our strategy involves imitating a portfolio of 15 most popular stocks among hedge funds and it has returned 118% since it went live in August 2012, beating the S&P 500 ETF (SPY) by some 60 percentage points (see more details here).

The first stock that we would like to mention in this article is TRACON Pharmaceuticals Inc (NASDAQ:TCON), which registered its boost on a volume of 1.49 million shares, above the average of just 52,300 shares. Earlier today, the clinical stage biopharmaceutical company said that its single patient Phase 2 clinical trial of TRC105, for the treatment of choriocarcinoma, showed that the drug had a complete response. TRACON is engaged in the development of novelty therapies for cancer. The results of the trial, which involved a 37-year old woman with persistent and unresectable metastatic choriocarcinoma, were presented at the 18th World Congress of Gestational Trophloblastic Diseases in Indonesia.

Hedge funds from our database are bullish on TRACON Pharmaceuticals Inc (NASDAQ:TCON) as they held over 11% of the company at the end of June. However, due to the company’s small size and weak financial results, it’s not very popular among the investors that we follow. During the second quarter, the number of funds with long positions in the company declined by two to five, and the total value of their holdings slid to $15.98 million from $20.24 million. Among these investors, the two largest stakes are held by James E. Flynn’s Deerfield Management and Jacob Gottlieb’s Visium Asset Management, which disclosed ownership of 485,000 shares and 436,300 shares in their latest 13F filings respectively. On the third spot is Daniel Gold’s QVT Financial, which owns 368,300 shares.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!